Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMV390048 in early Plasmodium falciparum infection
NCT02281344Phase 1Terminated
- Sponsor
- Medicines for Malaria Venture
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Countries
- 1
01
Overview
Phase 1, open-label trial of MMV390048 in Malaria, sponsored by Medicines for Malaria Venture. Primary endpoint: MMV390048 Area Under the Plasma Concentration Versus Time Curve up to Day 21 Post-dose. Started Oct 2014; status: terminated.
02
Drugs
MMV390048
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT02281344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281344.